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Abstract Contrast-enhanced ultrasound (CEUS) is
increasingly being used to evaluate patients with known or
suspected atherosclerosis. The administration of a
microbubble contrast agent in conjunction with ultrasound
results in an improved image quality and provides infor-
mation that cannot be assessed with standard B-mode
ultrasound. CEUS is a high-resolution, noninvasive imag-
ing modality, which is safe and may benefit patients with
coronary, carotid, or aortic atherosclerosis. CEUS allows a
reliable assessment of endocardial borders, left ventricular
function, intracardiac thrombus and myocardial perfusion.
CEUS results in an improved detection of carotid
atherosclerosis, and allows assessment of high-risk plaque
characteristics including intraplaque vascularization, and
ulceration. CEUS provides real-time bedside information
in patients with a suspected or known abdominal aortic
aneurysm or aortic dissection. The absence of ionizing
radiation and safety of the contrast agent allow repetitive
imaging which is particularly useful in the follow-up of
patients after endovascular aneurysm repair. New devel-
opments in CEUS-based molecular imaging will improve
the understanding of the pathophysiology of atherosclerosis
and may in the future allow to image and directly treat
cardiovascular diseases (theragnostic CEUS). Familiarity
with the strengths and limitations of CEUS may have a
major impact on the management of patients with
atherosclerosis.
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Introduction
Contrast-enhanced ultrasound (CEUS) is an increasingly
used imaging modality in cardiovascular medicine, and has
advantages for both cardiac and vascular imaging [1–3].
CEUS is characterized by the use of an ultrasound contrast
agent in conjunction with ultrasound imaging. The ultra-
sound contrast agent consists of gas filled microbubbles,
which resonate when exposed to an ultrasound beam.
CEUS can be used to improve the image quality of stan-
dard ultrasound or to obtain information that cannot be
assessed using standard ultrasound [4, 5].
CEUS has various potential applications in patients with
atherosclerosis (Table 1). In those with known or suspected
coronary artery disease, CEUS improves the delineation of
endocardial borders, allowing an accurate assessment of
left ventricular shape and function. The use of an ultra-
sound contrast also improves the image quality and diag-
nostic accuracy of stress echocardiography. In patients with
a previous myocardial infarction, CEUS is useful to assess
intracardiac thrombus, which may have important clinical
implications.
In patients with known or suspected carotid atheroscle-
rosis, CEUS can be used to assess the presence and extent
of atherosclerosis. Moreover, CEUS allows to characterize
the atherosclerotic plaque and evaluate factors that are
associated with plaque rupture, including assessment of
plaque surface, plaque ulceration and intraplaque
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vascularization. Furthermore, CEUS imaging can further
increase the diagnostic performance in different aortic
pathologies, particularly the detection and characterization
of endoleaks following endovascular treatment of abdom-
inal aortic aneurysms (AAAs).
This review of literature will explain the principles and
ultrasound acquisition settings, and will focus on cardiac
and vascular including carotid and aortic applications of
CEUS.
Principles and settings of CEUS
Ultrasound contrast agents
A number of ultrasound contrast agents has been
developed and is commercially available. The ultra-
sound contrast agent typically consists of microbubbles
with a protein or lipid shell filled with an inert gas.
These microbubble contrast agents are stable, and are
strong reflectors and resonators when exposed to an
ultrasound beam. An overview of commercially avail-
able contrast agents is provided in Table 2. The safety
of intravenous administration of an ultrasound contrast
agent has been confirmed in millions of patients [6, 7].
Contraindications for the administration of the contrast
agents are: known allergy to the contrast agent, large
right to left shunt, and an unstable clinical condition. It
is recommended to use a protocol in the echo laboratory
for early recognition of side-effects and so that in the
event of an allergic reaction immediate treatment can be
started [8].
Ultrasound system settings
The currently available high-end ultrasound systems have
preprogrammed settings for CEUS. These settings can be
slightly adapted to optimize the CEUS study. To avoid
destruction of the microbubbles, which are fragile, a low
mechanical index (0.1–0.3) or middle-high (0.3–0.5)
mechanical index is selected [8]. A low mechanical index
allows continuous image acquisition, whereas a middle-
high mechanical index requires intermittent imaging (for
example acquisition of 1 frame every 2 or 3 cardiac cycles)
allowing the replenishment of destructed microbubbles.
Depending on the ultrasound system settings, harmonic
imaging is used which is based on differences in ultrasound
reflection by tissue and by the contrast agent. The contrast
agent does not only reflect the ultrasound at the transmitted
frequency but also at higher harmonic frequencies, allow-
ing to distinguish contrast agent from tissue. Other con-
trast-specific ultrasound methods are based on the
transmission of multiple ultrasound pulses. Mostly, a
combination of pulses is transmitted which are out-of-
phase (pulse inversion), or differ in amplitude (power
modulation), depending on the manufacturer of the ultra-
sound system.
Table 1 Overview of clinical application of contrast-enhanced ultrasound in cardiovascular diseases
Field of
application
Clinical indication
Cardiac Endoluminal border delineation to assess left ventricular volumes and function and detection of intracardiac thrombus
Visualization of wall motion and thickening to assess myocardial ischemia and viability
Quantification of myocardial perfusion
Carotis Endoluminal border delineation to depict hypoechogenic plaques, plaque irregularities and ulcerations, distinguish very high-
grade stenosis from complete occlusion
Detection and quantification of intraplaque neovascularization to risk stratify atherosclerotic lesions and to monitor
therapeutic effects
Aorta Detection of dissection membrane and re-entry and discrimination of true and false lumen in abdominal aortic dissection
Endoluminal border delineation in abdominal aortic aneurysm to detect intraluminal thrombus
Detection and classification of endoleaks after endovascular aortic aneurysm repair (EVAR)
Table 2 Overview of
commercially available
ultrasound contrast agents
Contrast agent Manufacturer Shell Gas
Definity Lantheus medical imaging Lipid Octafluoropropane
Levovist Schering AG Galactose Air
Optison GE healthcare Albumin Octafluoropropane
SonoVue Bracco diagnostics Lipid Sulfurhexafluoride
Sonazoid GE healthcare Lipid Perfluorocarbon
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CEUS acquisition
After explanation of the imaging modality and obtaining
informed consent of the patient, the CEUS examination can
be started. First, a venous infusion line is placed, and after
preparation of the contrast agent according to the instruc-
tions of the manufacturer, the ultrasound contrast agent is
administered intravenously. The ultrasound contrast agent
can be injected as a bolus which is practical and will give
good imaging results in most circumstances. Alternatively,
the ultrasound contrast agent can be administered using a
continuous infusion, which provides a stable concentration
of contrast agent in the circulation and therefore has
advantages for the assessment of myocardial perfusion.
After intravenous administration, the ultrasound contrast
agent travels through the cardiovascular system. The
microbubbles behave as red blood cells and are strict
intravascular tracers. Because of their small diameter, the
microbubbles are able to pass the pulmonary circulation.
After administration, the contrast agent can be visualized
for minutes. When the microbubbles are shattered, the shell
is removed through the reticuloendothelial system, while
the inert gas is exhaled.
CEUS: cardiac applications
Endocardial border delineation
Assessment of left ventricular volumes and function
An accurate detection of the endocardial border is highly
relevant in patients with known or suspected coronary
artery disease. Up to 15 % of these patients have a mod-
erate to poor image quality at standard echocardiography,
because of comorbidity such as obesity and chronic pul-
monary disease. CEUS significantly improves the detection
of the endocardial border, which is clinically relevant for
an accurate assessment of left ventricular volumes and
systolic left ventricular function [9]. The use of an ultra-
sound contrast agent improves the assessment of the left
ventricular ejection fraction, and thereby has an impact on
clinical care [10]. Among other parameters, the left ven-
tricular ejection fraction determines the medical treatment,
therapy with an implantable cardioverter defibrillator and
finally the prognosis of the patients.
Contrast stress echocardiography
Stress echocardiography provides information on the pres-
ence and extent of myocardial ischemia. Moreover, stress
echocardiography allows assessment of myocardial viability
in patients with ischemic cardiomyopathy. A good
visualization of wall motion and thickening is needed for an
accurate interpretation of stress echocardiography. Because
the criteria for myocardial ischemia and myocardial viabil-
ity are based on wall motion abnormalities, an accurate
visualization of all walls of the left ventricle is required.
Ultrasound contrast agents provide an improved endocardial
border delineation, and result in a better reproducibility in
wall motion analysis even by less experienced readers
[11, 12]. The use of an ultrasound contrast agent is recom-
mended during stress echocardiography in all patients with
suboptimal image quality, in whom C 2 segments of the left
ventricle are not adequately visualized. The administration
of an ultrasound contrast agent is particularly relevant for
visualization of the anterior and lateral wall, because image
quality is often suboptimal in those areas.
Intracardiac thrombus
In patients with ischemic cardiomyopathy and a suspected
intracardiac thrombus, CEUS may be highly useful. In
these patients the endocardial border in the left ventricular
apex is frequently difficult to delineate, and clutter or
reverberation artefacts near the apex may be present during
standard echocardiography. CEUS allows a reliable
assessment of the left ventricular cavity and can be used to
exclude or confirm the presence of an intracardiac throm-
bus (Fig. 1). A study in 409 patients demonstrated that
standard echocardiography was nondiagnostic for the
exclusion or detection of thrombus in 46 % of the cases; a
selection of these patients subsequently underwent CEUS,
and the addition of an ultrasound contrast agent led to a
diagnostic study in 90 % of the cases [13]. Recent multi-
modality imaging studies have confirmed that CEUS has a
higher diagnostic accuracy compared to standard echocar-
diography for the assessment of intracardiac thrombus, and
demonstrated that contrast-enhanced magnetic resonance
imaging may be even superior [14, 15].
The evaluation of cardiac thrombus by CEUS may have
a direct impact on the management of the patient, and may
lead to changes in medical therapy (anticoagulation).
Additionally the detection of an intracardiac thrombus by
CEUS may prevent defibrillation threshold testing in
patients with an implantable cardioverter defibrillator
(ICD).
Myocardial perfusion imaging
In patients with known or suspected coronary artery dis-
ease, CEUS may be useful for the assessment of myocar-
dial perfusion (Fig. 2) [16]. Myocardial perfusion imaging
requires a stable concentration of the ultrasound contrast
agent in the circulation, that can be best achieved with
intravenous administration using a continuous pump
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infusion system. After a high mechanical index ultrasound
flash to destruct all intramyocardial ultrasound contrast
agent, the replenishment of the contrast agent into the
myocardium is recorded. Several software packages were
developed to measure the video-intensity of the myocardial
perfusion replenishment and to quantify myocardial per-
fusion defects. Although CEUS myocardial perfusion
imaging has been successfully used in multiple studies
[16, 17], the use of this imaging modality for this specific
application clinical practice is still limited by a relatively
high intra- and interobserver variability.
CEUS: carotid applications
Standard carotid ultrasound
In daily routine, the use of standard carotid ultrasound to
detect atherosclerotic wall alterations including carotid
Fig. 1 Assessment of an intracardiac thrombus using CEUS. A
61-year old man with a history of a large apical-anterior myocardial
infarction was referred for echocardiography for the evaluation of
cardiac thrombus. a Standard echocardiography (apical 4 chamber
view) demonstrates an abnormality in the left ventricular apex which
was a suspected thrombus (arrow). b CEUS demonstrates that there is
actually no thrombus in the left ventricular apex. The abnormality that
was observed on standard echocardiography was probably a rever-
beration artefact
Fig. 2 Assessment of myocardial perfusion using CEUS. Example of
an abnormal myocardial perfusion echocardiogram. a Apical three
chamber view. After administration of the contrast agent, a high
mechanical index flash is given to destroy the contrast agent that is
present in the myocardium. Thereafter, the left ventricular
myocardium does contain no or only a limited amount of contrast
agent. Ao aorta, LV left ventricle, RV right ventricle. b After a short
period, the myocardium is filled with blood and contrast agent. There
is an apical and lateral perfusion defect visible (arrows), indicating a
significant coronary stenosis. Example reproduced from [84]
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plaques and stenosis is well established. The main focus of
such an investigation is the measurement of Doppler
velocities within carotid lesions in order to determine the
grade and therefore also the severity of the stenosis. Beside
this morphological and hemodynamic information on
conventional ultrasound which represent s a late manifes-
tation of atherosclerosis, also early changes of the
atherosclerotic process can be depicted by using high fre-
quency B-mode ultrasound. It is well known that small
changes in thickening of the carotid intima-media (c-IMT)
can be detected using this imaging method, and represent
an early surrogate marker of systemic atherosclerosis [18].
Furthermore, B-mode ultrasound can also be useful not
only to detect but also to characterize atherosclerotic pla-
que by identifying surface irregularities and echogenicity
of the lesion itself. In large prospective epidemiological
studies, it has been shown that an increased c-IMT is
associated with future cerebrovascular and cardiac events
[19]. However, in addition to the traditional cardiovascular
risk factors to predict individuals risk, the measurement of
c-IMT has limited value [20]. On the other hand, the
combination of c-IMT and the presence of carotid plaque
has the potential to significantly increase risk prediction in
addition to traditional cardiovascular risk factors
alone [21].
Nevertheless, it is still controversial if the incorporation
of c-IMT and carotid plaque to cardiovascular risk
assessment strategies is really beneficial in the clinical
setting [22]. Therefore, it seems to be useful to include
further plaque characteristics which can be analyzed by
ultrasound imaging for a better risk stratification of indi-
vidual patients [23]. Based on different studies, patients
with hypoechoic carotid lesions and plaque ulcerations on
B-mode ultrasound have more cerebrovascular and cardiac
events in the future, and therefore, this kind of alterations
are associated with higher cardiovascular risk [3, 24–27].
CEUS for luminal enhancement of the carotid artery
During the last years CEUS imaging of the carotid artery
has been widely investigated in order to analyze carotid
plaque characteristics in more detail compared to stan-
dard ultrasound alone. Usually, a linear vascular ultra-
sound probe with medium frequency (e.g. 3–9 MHz) is
most suitable for carotid artery imaging with CEUS.
Typically, on CEUS imaging the carotid lumen is
enhanced shortly after injection of the contrast agent. The
adventitia layer also appears enhanced, whereas the
intima-media layer remains hypoechogenic. Using this
imaging technique, smaller vessel wall irregularities and
hypodense plaques, as well as plaque ulcerations can be
depicted much better than using standard ultrasound
alone [28] (Fig. 3).
Recently, asymptomatic patients with high cardiovas-
cular risk have been investigated using carotid CEUS
imaging in order to detect subclincal atherosclerotic lesions
[29]. The researchers found that this additional use of
CEUS increases the detection rate of predominantly
hypoechogenic carotid plaque. Therefore, carotid CEUS
may be useful to evaluate patients for subclinical
atherosclerosis. Furthermore, different reports also
emphasize that CEUS imaging could be very useful to
separate a carotid occlusion from a very narrow stenosis
[30, 31]. Carotid CEUS imaging could also be very bene-
ficial for analyzing restenosis after carotid stenting [32].
CEUS for carotid plaque neovascularization
Carotid CEUS imaging is not only useful for better delin-
eation of the endoluminal border of the carotid artery but
also for a deeper analysis of plaque characteristics by
visualizing the microvessels within the atherosclerotic
lesion itself [2]. These microvessels have been known to be
derived from the physiological existing vasa vasorum in
the adventitia layer of the large- and middle-size arteries
which can proliferate into the atherosclerotic plaque. In
different histological studies, the increase of intraplaque
neovascularization has been investigated and seems to be
triggered by hypoxia and inflammation. Importantly, pla-
que progression and vulnerability, eventually leading to the
vascular event seems to be closely related with this intra-
plaque neovascularization [33]. Particularly in symp-
tomatic carotid stenosis, such microvessels of larger
amount have been documented. Interestingly, this network
of small vessels seems of immature nature and leakier than
normal microvessels which make such plaque more prone
for inflammatory cell recruitment and intraplaque hemor-
rhage, eventually leading to plaque rupture and vascular
event. Hellings and co-workers published an important
prospective study in which specific histological character-
istics of carotid stonsis after carotid endarterectomy were
analyzed with regard to future vascular events [34].
Patients with higher vessel density and more intraplaque
hemorrhage on histology had during the 3 years follow-up
more vascular events. These results emphasize again that
higher neovascularization within the carotid atherosclerotic
plaque seems to be a marker of cardiovascular vulnerability
with a certain prognostic importance. Therefore, imaging
modalities which help to visualize intraplaque neovascu-
larization non-invasively could be very useful for further
stratification and prevention of cardiovascular risk [2, 35].
Particularly, carotid CEUS imaging seems to be of great
value for the identification and quantification of such
microvessels within carotid arteriosclerotic lesions. Several
researchers analyzed this intraplaque neovascularization on
CEUS imaging in different animal models [36–38] and also
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in patients scheduled for carotid endarterectomy [39, 40].
They found good correlations between the grade of intra-
plaque neovascularization on CEUS and the amount of
microvessels on histology. Usually, the degree of intra-
plaque neovascularization on CEUS was determined based
on a visual interpretation using a scoring system for the
grading (e.g. no, moderate, extensive enhancement)
(Fig. 4). Some investigators tried to quantify the degree of
intraplaque neovascularization by measuring video-inten-
sity within the atherosclerotic lesion [41–43]. They also
documented a very good correlation between this quanti-
tative approach to measure the degree of intraplaque neo-
vascularization and microvessel density on histology.
Recently, van den Oord published the results of a new
quantification tool based on custom developed software
which uses a motion tracking algorithm [44]. Such a more
accurate quantitative analysis method to assess intraplaque
neovascularization seems to be mandatory for clinical
application of CEUS imaging in the future. Interestingly, the
researchers found also a good correlation between the
degree of intraplaque neovascularization using this quan-
tification tool and the previous mentioned visual based
approach on carotid CEUS imaging. This assessment seems
also to be very reproducible with low intra-observer and
inter-observer variability. Similar to this study, other studies
used also a quantitative software based approach to deter-
mine the degree of intraplaque neovascularization on carotid
CEUS imaging [45, 46]. They found a good correlation with
histological analysis of plaque vascularization, too.
Our research group also analyzed almost 300
atherosclerotic carotid lesions with standard ultrasound and
CEUS imaging [47]. We measured intraplaque neovascu-
larization on CEUS using the previously mentioned visual
based scoring system (no, moderate or extensive
enhancement). In line with previous published results and
with the concept that hypoechoic plaques were more vul-
nerable, we found that echogenicity on B-mode ultrasound
was inversely correlated with the degree of intraplaque
neovascularization on CEUS. Hypoechoic plaques were
significantly more often more vascularized on CEUS
imaging. We also revealed that more severe atherosclerotic
lesions based on the degree of stenosis and plaque thick-
ness were also more vascularized on CEUS imaging
(Fig. 5). One recent study also documented that neovas-
cularization within carotid stenosis detected by CEUS was
associated with the presence of microembolic signals
known as another marker of plaque vulnerability using
transcranial color Doppler monitoring [48].
Furthermore, clinical vascular symptoms have been cor-
related with the presence of intraplaque neovascularization
Fig. 3 Assessment of vessel wall irregularities and plaque ulcerations
on carotid artery using CEUS. a Mixed hypo- and hyperechoic
plaques at the carotid bulb on B-mode ultrasound (right side) and
CEUS imaging (left side) with surface irregularities (arrows).
b Plaque ulceration (arrow) on CEUS imaging (left side) at the
origin of the internal carotid artery not detected on B-mode ultrasound
(right side)
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on CEUS. Retrospective studies including our own have
shown pronounced intraplaque neovascularization on carotid
CEUS imaging in patient with past cerebrovascular and
coronary events [43, 49–52]. This result supports the con-
cept that the vascular risk assessment based on the carotid
vessel wall alterations, particularly the degree of intraplaque
neovascularization is not limited to the cerebrovascular bed
but also generalizable to the coronary and maybe also the
peripheral vascular system.
The use of carotid CEUS imaging to assess intraplaque
neovascularization in order to have a new, non-invasive
tool for better risk stratify carotid lesions and patients has
been recommended by the latest EFSUMB guidelines on
the clinical practice of CEUS on non-hepatic applications
[53]. Even though there are no clinical date, the guidelines
also emphasize the benefit of carotid CEUS imaging also
for the assessing the response to anti-atherosclerotic ther-
apy. Interestingly, recent published paper demonstrated in
rat model, that atorvastatin significantly inhibits the
development of adventitial vasa vasorum and progression
of atherosclerosis measured by CEUS and intravascular
ultrasound imaging independent of lowering the choles-
terol level [54]. Therefore, monitoring of atherosclerotic
lesions by CEUS imaging could indeed be clinically ben-
eficial in the future.
Actual good clinical indication for CEUS imaging is the
detection of small hypoechoic and ulcerated plaque by a
better delineation of the endovascular border based on the
luminal enhancement. Furthermore, CEUS imaging for the
quantification of intraplaque neovascularization seems to
Fig. 4 Visual based grading of intraplaque neovascularization on
CEUS imaging. a No enhancement: Small plaque on the fare wall of
the internal carotid artery on B-mode ultrasound (right side) without
intraplaque neovascularization on CEUS imaging (left side). bModer-
ate enhancement: Mixed hypo- and hyperechoic plaques at the carotid
bulb on B-mode ultrasound (right side) and CEUS imaging (left side)
with moderate intraplaque neovascularization on the plaque shoulder
(arrows). c Extensive enhancement: Hypoechoic plaque at the origin
of the internal carotid artery on B-mode ultrasound (right side) and
CEUS imaging (left side) with extensive intraplaque neovasculariza-
tion including the plaque core (arrows)
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be a good tool for better risk stratification of atherosclerotic
carotid stenosis and patients with carotid plaques. This
strategy could improve the prediction of future vascular
events and may be helpful for better treatment selection.
Particularly, in patients with asymptomatic carotid steno-
sis, CEUS imaging could be beneficial to select those
patients who should assign for carotid endarterectomy or
stenting. However, further prospective randomized studies
to analyze this approach are mandatory before incorporat-
ing such a concept in a daily clinical algorithm.
CEUS: aortic applications
Also the use of standard ultrasound in the diagnostic
approach of the abdominal aorta is well established. In
recent years the use of CEUS increasingly allowed a more
differentiated view of the aortic wall by a better demar-
cation of the aortic lumen and its branches. In the following
part we will discuss the main implications of CEUS in
imaging different atherosclerotic pathologies of the
abdominal aorta.
Aneurysm dissecans
The clinical presentation of a dissection of the abdominal
aorta varies widely and the prediction of the progression of
a dissection is challenging, and therefore more than one-
third of aortic dissections remain initially undetected
and nearly 30 % are diagnosed post mortem by autopsy
[55–57].
Due to its high spatial resolution and its high rating in
routing therapy the definite diagnosis or the exclusion of an
aortic dissection is made by computed tomography
angiography (CTA). Conventional ultrasound is helpful in
early stages of finding the diagnose in an emergency set-up
with suspected dissection of the abdominal aorta, whereas
the addition of contrast agent leads to a better differentia-
tion of true and false lumen, because the latter, if not full of
thrombus, usually shows contrast flow during late phase or
at least with noticeable detention [58]. Clevert et al. [59]
evaluated 35 patients with abdominal aortic dissection
using standard ultrasound, CEUS imaging and CTA. They
found that sensitivity of CEUS imaging to detect dissection
Fig. 5 Intraplaque
neovascularization within
carotid stenosis on CEUS
imaging. a 77-year-old patient
with asymptomatic high-grade
stenosis at the origin of the right
internal carotid artery on
Duplex ultrasound. b Extensive
intraplaque neovascularization
within the carotid stenosis at the
near wall on CEUS imaging
(arrows) and moderate
neovascularization at the fare
wall (arrow)
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membrane was 97 % using CTA as gold standard which
was much better than standard ultrasound alone (sensitivity
68 %). Particullarly, in search of the entry or re-entry of the
dissection, CEUS can be used, especially to detect small
dissection membranes, which were not able to be visual-
ized with B-Mode or color Doppler.
Aneurysm verum
Over the last decade standard ultrasound was not only
entrenched as a screening method for AAA but also as a
valid method during its routine follow-up [57]. Different
clinical reports have showed the importance of CEUS in
imaging the aneurysm sack with its perfused lumen and the
distinction of thrombotic structures [56, 58]. Interestingly,
even in the setting of ruptured aortic aneurysm, it seems,
that collecting contrast-specific images such as enhance-
ment of the aortic wall or contrast containing extravasates
preoperatively does not delay surgery [60].
Endovascular aortic aneurysm repair (EVAR)
and Endoleak
Catheter based endovascular aneurysm repair (EVAR) is
meanwhile a worldwide established alternative to conven-
tional open surgery replacement in treating an aortic
aneurysm and provides a minimal invasive option espe-
cially in patients with fitting characteristics of the
aorta [61].
However, EVAR shows to a certain extent complica-
tions that are procedure associated and gain in relevance
especially with prolonged survival. These are predomi-
nantly so called endoleaks which occur in up to 45 % of the
cases and are characterized by a persistent blood flow into
the aneurysm sac from outside the endoprothesis [62].
Here, a progressive aneurysmal enlargement by flow-in-
duced pressure increase could lead to a relocation of the
stent graft or in the further course even to the rupture of the
aneurysm sac. Therefore, the detection of such an
enlargement of the aneurysm sac makes a reintervention
often necessary. Nowadays, complication controls are often
made by contrast CTA [63]. However, because of the
radiation burden as well as the potentially nephrotoxic
effect of the contrast medium with frequent use, the role of
routine follow-up of patients using CTA is controversial
[64]. The long term prognosis after EVAR is strongly
dependent on the renal function and could be compromised
by repetitive application of CT-specific contrast agents, and
therefore CEUS appears to be an enticing option [65].
CEUS allows the real-time assessment of flow, which is
highly useful for the detection and classification of endo-
leaks (Fig. 6). A meta-analysis showed an accumulated
specificity of 98 %, respectively a sensitivity of 88 %, for
the finding of an endoleak and the authors stated a supe-
riority of CEUS in comparison with standard ultrasound,
which is congruent with previously collected data [65, 66].
Due to the strictly intravascular distribution and reso-
nance pattern of the contrast agent, CEUS can also be used
for detection of endoleaks that are difficult or even
impossible to be displayed by CTA due to low flow rates.
In one study, CEUS was used additionally in a small
number of patients that did not show any signs of endoleak
or endograft irregularities during CTA despite increase in
aneurysm diameter after EVAR and surprisingly revealed
in 100 % of the participants an endoleak and helped to
classify it correctly in 80 % of the cases. Results were
confirmed by a final subtraction angiography and led to the
conclusion that in the event of an unclear aneurysm
enlargement after EVAR, CEUS represents a promising
diagnostic tool [67]. In addition, CEUS can also be used
intraoperatively for early detection of endoleaks or to find
appropriate landing zones during EVAR and so important
information can be collected to carry out immediately a
correction of the stent position during the intervention
[68, 69].
Another application in the field of CEUS for endoleak
detection, especially to differentiate those with variable
flow rates, is the by contrast harmonic imaging optimized
perfusion analysis [70]. Hereby, reperfusion of abdominal
aneurysm sac after EVAR is determined by a time intensity
curve, which, in turn, is derived from bolus administration
of contrast agent.
CEUS for post-interventional follow-up after EVAR
In general, CEUS is at least equated to CTA in the diag-
nostic performance in terms of recognition and classifica-
tion of endoleaks. This led to the conclusion of some
authors that for future references CEUS might play a
deciding role in post-interventional follow-up after EVAR
[71]. In a prospective observational study of more than 100
patients after EVAR to examine the accuracy rate of var-
ious diagnostic procedures compared to conventional
angiography CEUS proved as superior against color Dop-
pler and as equivalent against CTA or MRA [72]. More-
over, the authors even conclusively stated a superiority of
CEUS in comparison to CTA with respect to the classifi-
cation of endoleaks. This is in turn connected to another
smaller analysis, in which patients after EVAR were
examined over a longer period of time on endoleaks,
whereby even insidious ones or those with low flow could
be visualized. However, due to continuous administration
of contrast medium here instead of basal-bolus principle
the examination window has been extended in time, thus
allowing a more precise consideration [73]. The accuracy
of CEUS in the recognition and classification of endoleaks
Int J Cardiovasc Imaging (2016) 32:35–48 43
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after EVAR seems to be high, as recently demonstrated
prospectively with a sensitivity of 97 %, a specificity of
100 % and an accuracy of 99 % [74].
3D-CEUS for endoleak detection
As a further development of CEUS, a novel technique for
three-dimensional CEUS (3D-CEUS) utilizes positional
information from magnetic field emitters to assemble all
ultrasonic reflections into a high-definition three-dimen-
sional image [75]. Ormesher et al. [76] stated, that in patients
undergoing conventional infrarenal EVAR electively this
3D-CEUS technique allows intraoperatively the detection of
endoleaks not seen on unipolar digital subtraction angiog-
raphy and is more sensitive in finding the source of endoleak
than conventional CEUS. This led to the authors implication
that 3D-CEUS has the potential to complement or even to
replace digital subtraction angiography in this context as
final imaging in reduction of x-ray contrast. In another study,
which was conducted by the same research group, the
authors conclude that 3D may be more sensitive in assessing
an endoleaks after EVAR than 2D CEUS or CTA [75].
Hopes for the future are through the use of CEUS peri-
interventionally during EVAR to improve risk stratification
with respect to the occurrence of complications, so that
therapy management or the follow-up intervals can be
individually customized.
Future directions in cardiovascular CEUS
Ultrasound imaging using microbubbles which are targeted
with monoclonal antibodies to specific ligands could fur-
ther improve and expand the diagnostic prospects of cur-
rent cardiovascular ultrasound examination in the future.
The use of such targeted microbubbles may allow non-
invasively investigating specific molecular processes that
play a role in the pathophysiology of cardiovascular dis-
eases [77].
In atherosclerosis, targeted microbubbles have been
examined in the assessment of thrombosis, neoangio-
genesis and inflammation in various animal models.
Wang and co-workers investigated CEUS imaging with
glycoprotein IIb/IIIa-targeted microbubbles which bind
specifically to activated platelets [78]. They imaged the
carotid artery in a mice model after thrombus induction
and after thrombolysis. This imaging method allowed
real-time molecular imaging of acute arterial thrombosis
and monitoring of the success or failure of
Fig. 6 Endoleak after
endovascular aortic aneurysm
repair on CEUS imaging. a Typ
2 endoleak with enhancement of
the aneurysm sac (arrow)
caused by retrograde flow form
a lumbar artery on CEUS
imaging (left side) and
corresponding B-mode
ultrasound (right side). b Typ 1
endoleak with enhancement of
the aneurysm sac (arrow) by an
incomplete seal at the proximal
end of the graft (main body) on
CEUS imaging (left side) and
corresponding B-mode
ultrasound (right side)
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pharmacological thrombolysis in vivo. In a mouse model
of age-dependent atherosclerosis, ultrasound molecular
imaging of the proximal thoracic aorta was performed
with microbubbles targeted to P-selectin and VCAM-1 in
order to detect a lesion-prone vascular phenotype [79].
Both, P-selectin and VCAM-1 are involved in the regu-
lation of leukocyte trafficking. This is an early step in
inflammatory process involved in plaque formation. The
researchers found that this targeted microbubbles prefer-
entially bind to regions of lesion formation. Using this
same mouse model, targeted microbubbles to VCAM-1
for CEUS imaging was used to investigate also the effect
of statins to this early atherosclerosis process [80]. Less
endothelial expression of VCAM-1 and reduced plaque
burden was found in statin treated animals. Accordingly,
signal enhancement by CEUS molecular imaging was
detected only in non-treated, but not in statin-treated
animals. Monitoring these early changes of an activated
and inflamed endothelium during the atherosclerotic
process is appealing and has already made its way to
preclinical studies in non-human primates [81]. Molecu-
lar ultrasound imaging has also been used to investigate a
later stage of atherosclerotic disease by using VEGF-re-
ceptor targeted microbubbles in order to detect neovas-
cularization on the abdominal artery plaques in rabbits
[82]. This could be helpful to better risk stratify
atherosclerotic lesions by imaging more specifically vul-
nerable plaques. However, no clinical studies using
molecular ultrasound imaging in cardiovascular disease
have been performed so far. Therefore, further studies are
needed to bring the targeted microbubbles technology
successfully forward from the laboratory to the clinical
setting.
Moreover, ultrasound contrast agent has the potential to
even further increase not only the diagnostic but also the
therapeutic capabilities of ultrasound technology in the
cardiovascular field. Several researchers are already
investigating ultrasound directed and site-specific gene and
drug delivery systems [83]. Particularly, the use of small
molecules or plasmid DNA for thrombolysis, anti-inflam-
matory or anti- or angiogenic treatment could have an
important clinical impact. Eventually, these newer tech-
niques of theragnostic CEUS with the possibility to
improve diagnostic imaging and directly treat the patient
could be of great clinical benefit in the field of
atherosclerosis.
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